Targeting the EGFR in neoplasia - More questions than answers

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 899-902

  Dicker, Adam P ^a,b   Rodeck, Ulrich ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; MATUZUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; HEAD AND NECK CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; RADIOSENSITIVITY; STRUCTURE ANALYSIS;

EID: 1242293096     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.07.009     Document Type: Conference Paper

References (19)

1. Downward J., Yarden Y., Mayes E., et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307:1984;521-527.
2. Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. 29:(Suppl. 14):2002;3-9.
3. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 7:(Suppl. 4):2002;2-8.
4. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 110:2002;669-672.
5. Bunn P.A. Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol. 29:(Suppl. 14):2002;38-44.
6. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:1995;183-232.
7. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer. 37:(Suppl. 4):2001;S9-S15.
8. Cohen R.B. Epidermal growth factor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2:2003;246-251.
9. Redemann N., Holzmann B., von Rüden T., et al. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol Cell Biol. 12:1992;491-498.
10. O'Dwyer P.J., Benson A.B. III. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol. 29:(Suppl. 14):2002;10-17.
11. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(Suppl. 18):1s-13s.
12. Rodeck U., Herlyn M., Herlyn D., et al. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor Immunologically mediated and effector cell-independent effects . Cancer Res. 47:1987;3692-3696.
13. Murthy U., Basu A., Rodeck U., et al. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys. 252:1987;549-560.
14. Clynes R.A., Towers T.L., Presta L.G., et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 6:2000;443-446.
15. Iwata KK, Provoncha K, Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva) [Abstract]. Proc Am Soc Clin Oncol 2002;21:21a.
16. González G., Crombet T., Catalá M., et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein Report of a pilot clinical trial . Ann Oncol. 9:1998;431-435.
17. DeSimone PA, Bence AK, Anderson EB, et al. A phase I study to investigate safety, tolerability and pharmacokinetics of single and escalating doses of GW572016 in healthy volunteers [Abstract]. Proc Am Soc Clin Oncol 2002;21:94a.
18. Herbst R.S., Kies M.S. ZD1839 (Iressa™) in non-small cell lung cancer. Oncologist. 7:(Suppl. 4):2002;9-15.
19. Oncologic Drugs Advisory Committee. Questions to the committee. NDA 21-399; ZD 1839 Iressa©(gefitinib). September 24, 2002.